TD Cowen Downgrades Evelo Biosciences to Market Perform
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Joseph Thome has downgraded Evelo Biosciences (NASDAQ:EVLO) from Outperform to Market Perform.

October 18, 2023 | 8:45 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Evelo Biosciences has been downgraded by TD Cowen from Outperform to Market Perform, which may negatively impact the stock's performance.
Analyst ratings often influence investor sentiment and can impact a stock's price. A downgrade from Outperform to Market Perform suggests that the analyst believes the stock will now perform in line with the market, rather than outperforming it. This could lead to a decrease in investor interest and a potential drop in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100